000281872 001__ 281872
000281872 005__ 20251127142638.0
000281872 0247_ $$2doi$$a10.1055/a-2698-5992
000281872 0247_ $$2pmid$$apmid:41197657
000281872 0247_ $$2ISSN$$a0720-4299
000281872 0247_ $$2ISSN$$a0015-8194
000281872 0247_ $$2ISSN$$a1439-3522
000281872 037__ $$aDZNE-2025-01243
000281872 041__ $$aGerman
000281872 082__ $$a150
000281872 1001_ $$00000-0001-5785-9594$$aHansen, Niels$$b0
000281872 245__ $$aNeues zur Blutbiomarker gestützten Frühdiagnostik der Vorstufen einer Alzheimer-Demenz | News on blood biomarker-based early diagnosis of the preliminary stages of Alzheimer's dementia
000281872 260__ $$aStuttgart [u.a.]$$bThieme$$c2025
000281872 3367_ $$2DRIVER$$aarticle
000281872 3367_ $$2DataCite$$aOutput Types/Journal article
000281872 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764249965_8033$$xReview Article
000281872 3367_ $$2BibTeX$$aARTICLE
000281872 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281872 3367_ $$00$$2EndNote$$aJournal Article
000281872 520__ $$aThe early diagnosis of Alzheimer's disease (ADD) has gained new significance through the further discovery of blood biomarkers. Blood biomarkers are less expensive, can be measured fully automatically with high throughput, are less invasive and provide faster information on specific dementia biomarkers than current methods used in routine clinical practice such as amyloid positron emission tomography (PET) or CSF examination of underlying pathological changes in Alzheimer's disease (AD) in patients with cognitive impairment. The aim of this review is to provide a presentation of the added value of blood-based biomarkers for the early diagnosis of ADD. Individual blood biomarkers are presented regarding their diagnostic reliability and predictive value for the diagnosis of AD in precursors of ADD ranging from subjective cognitive impairment (SCD) to mild cognitive impairment (MCI). In addition, the revised criteria for the diagnosis and staging of AD are discussed. Markers of tau pathology such as a phosphorylated tau protein 217 (p-tau217), a phosphorylated tau protein 181 (p-tau181), a phosphorylated tau protein 231 (p-tau231), but also amyloid-β (Aβ) markers such as the ratio of Aβ1-42/ 1-40 are described as specific biomarkers for the early diagnosis of AD. In addition, new amyloid peptide ratios such as Aβ-3-42/-3-40 are discussed, which may provide more insights into the pathogenesis of AD, as this N-terminal elongated Aβ peptides are cleaved from the amyloid precursor protein via a biochemical oligodendroglia-dependent pathway (ADAMTS4=disintegrin and metalloproteinase with thrombospondin motifs 4), which is important in AD pathophysiology due to oligodendroglia involvement. In addition, new promising composite hybrid ratios are explained, which could provide advantages in the early diagnosis of AD, such as the AT217-term or the AT181-term, which relates Aβ1-40 to Aβ1-42 and multiplies it by p-tau217 and p-tau181, respectively. Overall, the review provides an overview of the potential of blood biomarkers in the early diagnosis of ADD. However, these biomarkers should not be used alone for early diagnosis, but should always be evaluated in conjunction with other tests such as cerebrospinal fluid analysis.
000281872 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281872 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281872 650_7 $$2NLM Chemicals$$aBiomarkers
000281872 650_7 $$2NLM Chemicals$$atau Proteins
000281872 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000281872 650_2 $$2MeSH$$aHumans
000281872 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000281872 650_2 $$2MeSH$$aAlzheimer Disease: blood
000281872 650_2 $$2MeSH$$aBiomarkers: blood
000281872 650_2 $$2MeSH$$aEarly Diagnosis
000281872 650_2 $$2MeSH$$atau Proteins: blood
000281872 650_2 $$2MeSH$$aAmyloid beta-Peptides: blood
000281872 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000281872 650_2 $$2MeSH$$aCognitive Dysfunction: blood
000281872 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b1$$eLast author$$udzne
000281872 773__ $$0PERI:(DE-600)2037701-0$$a10.1055/a-2698-5992$$gVol. 93, no. 11, p. 446 - 452$$n11$$p446 - 452$$tFortschritte der Neurologie, Psychiatrie$$v93$$x0720-4299$$y2025
000281872 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000281872 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281872 9141_ $$y2025
000281872 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-02$$wger
000281872 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFORTSCHR NEUROL PSYC : 2022$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000281872 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-02
000281872 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000281872 980__ $$ajournal
000281872 980__ $$aVDB
000281872 980__ $$aI:(DE-2719)1410006
000281872 980__ $$aUNRESTRICTED